- 询价
- Cancer Drug Targets ChIP PCR Array
- 上海
- 2025年12月30日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 服务名称：
Cancer Drug Targets ChIP PCR Array
- 提供商：
SAB
Human Cancer Drug Targets ChIP PCR Array
|
||||||||||||||
The Human Cancer Drug Targets EpiTect Chip qPCR Array profiles the histone modification status or “histone code” of 84 actively sought targets for anticancer therapeutics and drug development. Histone modifications define chromatin structure, and some correlate closely with the transcriptional activity of associated genes. In vitro screening of therapeutics for a given cancer type increasingly depends on not only the activity, but also the expression and epigenetic status of oncogenes. For example, histone deacetylase (HDAC) inhibitors induce tumor suppressor gene expression, slowing growth and proliferation, but could also increase oncogene expression. The choice to add HDAC inhibitors to a drug regimen can depend on the histone codes of the two gene classes. Cancer cells with oncogenes in a heterochromatin state may respond better to HDAC inhibitor treatment because these genes would not be expressed or easily induced. Comprehensively understanding how oncogenes contribute to tumor growth and survival on the molecular level requires a determination of the epigenetic mechanisms regulating their expression. Using chromatin immunoprecipitation and this real-time PCR Array, you can easily and reliably analyze the histone modification patterns associated with a focused panel of important cancer-related genes. The EpiTect Chip qPCR Arrays are intended for molecular biology applications. This product is not intended for the diagnosis, prevention, or treatment of a disease. |
||||||||||||||
PI-3 Kinases & Phosphatases: FRAP1 (MTOR), PIK3C2A, PIK3C3, PIK3CA.
Growth Factors & Receptors: EGFR, ERBB2, ERBB3, ERBB4, FIGF, FLT1, FLT4, IGF1, IGF1R, IGF2, KDR, KIT, PDGFRA, PDGFRB.
Drug Metabolism: ABCC1, GSTP1, PTGS2, TXN, TXNRD1.
G Protein Signaling: RHOA, RHOB.
Hormone Receptors: ESR1, ESR2, PGR.
Heat Shock Proteins: HSP90AA1, HSP90B1.
Receptor Tyrosine Kinase Signaling: AKT1, AKT2, GRB2.
Cathepsins: CTSB, CTSD, CTSL1, CTSS.
Cell Cycle: CDC2, CDC25A, CDK2, CDK4, CDK5, CDK7, CDK8, CDK9, MDM2, MDM4, TERT.
Topoisomerases, Type II: TOP2A, TOP2B.
Transcription Factors: ATF2, HIF1A, IRF5, NFKB1, TP53.
Protein Kinases: AURKA, AURKB, AURKC, PLK1, PLK2, PLK3, PLK4, PRKCA, PRKCB, PRKCD, PRKCE.
RAS Signaling: HRAS, KRAS, NRAS.
Histone Deacetylases: HDAC1, HDAC11, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8.
Poly ADP-Ribose Polymerases: PARP1, PARP2, PARP4, TNKS.
Structural Protein: NTN3.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Publishers, Chur, Switzerland. Williams, M., Mehlin, C., Raddatz, R., and Triggle, D.J. 2005. Receptor targets in drug discovery and development. In Burger's Medicinal Chemistry
Overview of Novel Anticancer Drug Targets
There has been an explosion in the number of potential molecular targets that can be explored for selective cancer treatment. The stage is now set to translate years of productive cancer research into more patient-friendly anticancer
(TF) – specific CRMs, which are spotted to produce a computed genomic CRM microarray. In parallel, the in vivo pool of targets of a given TF is isolated by ChIP and used as a probe for hybridization with the array generated. Here we describe ChEST
